The Baseline, Clinical, and Laboratory Parameters of Breast Cancer Subjects Infected with COVID-19 in Medan, Indonesia
DOI:
https://doi.org/10.3889/oamjms.2022.9116Keywords:
Breast cancer, Chemotherapy, COVID-19, Immunity, ImmunosuppressionAbstract
BACKGROUND: Cancer patients may be susceptible to COVID-19 infection due to decreased immune status. Breast cancer is the most common cancer in Indonesia, still has high admission, which increasing the risk of exposure to COVID-19.
AIM: Thus, this study aimed to identify hospitalized breast cancer patients diagnosed with COVID-19 infection 1 year after the pandemic.
METHODS: This is a cross-sectional study that was conducted in the Adam Malik General Hospital in Medan, Sumatera Utara, Indonesia. The enrolled subjects were those who previously histopathologically confirmed with breast cancer and having laboratory-confirmed COVID-19 infection The sources of baseline, clinical, and laboratory data were retrieved from the electronic medical records. Statistical analysis was performed using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS: A total of 17 female breast cancer subjects with COVID-19 infection were enrolled in this study. Mostly subjects were multiparity, highest education was junior high school, housewife, menopause, diagnosed in Stage IV, had metastasis in lung, and categorized luminal B with invasive cancer of non-special type. Most subjects showed mild clinical and radiological severity of COVID-19 infection. Low leukocyte, high neutrophil-to-lymphocyte, and high platelet-to-lymphocyte counts were significantly differed between alive and death outcome in the subjects.
CONCLUSION: The baseline and clinical characteristics of female breast cancer subjects with COVID-19 infection were similar to general characteristics in the population. The parameters of leukocyte, neutrophil-to-lymphocyte, and platelet-to-lymphocyte counts could be a valuable predictive parameters of mortality outcomes.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. https://doi.org/10.1016/j.annonc.2020.03.296 PMid:32224151 DOI: https://doi.org/10.1016/j.annonc.2020.03.296
Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central. PLos One. 2020;16(3):0249038. https://doi.org/10.1371/journal.pone.0249038 PMid:33765049 DOI: https://doi.org/10.1371/journal.pone.0249038
Badan Nasional Penanggulangan Bencana Republik Indonesia. Indonesia COVID-19 Hub Site. Available from: https://www.bnpb-inacovid19.hub.arcgis.com. [Last accessed on 2022 Apr 10].
Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452-5. https://doi.org/10.1097/COC.0000000000000712 PMid:32304435 DOI: https://doi.org/10.1097/COC.0000000000000712
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. https://doi.org/https://doi.org/10.3389/fimmu.2020.01441 PMid:32612615 DOI: https://doi.org/10.3389/fimmu.2020.01441
Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. https://doi.org/10.1016/j.cpcardiol.2020.100618 PMid:32439197 DOI: https://doi.org/10.1016/j.cpcardiol.2020.100618
Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, et al. COVID-19 in breast cancer patients: A cohort at the institut curie hospitals in the Paris area. Breast Cancer Res. 2020;22(1):55. https://doi.org/10.1186/s13058-020-01293-8 PMid:32460829 DOI: https://doi.org/10.1186/s13058-020-01293-8
Fratino L, Procopio G, Di Maio M, Cinieri S, Leo S, Beretta G. Coronavirus: Older persons with cancer in italy in the covid-19 pandemic. Front Oncol. 2020;10:648. https://doi.org/10.3389/ fonc.2020.00648 PMid:32426285 DOI: https://doi.org/10.3389/fonc.2020.00648
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-91. https://doi.org/10.1158/2159-8290.CD-20-0422 PMid:32345594 DOI: https://doi.org/10.1158/2159-8290.CD-20-0422
Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504. https://doi.org/10.1016/j.intimp.2020.106504 PMid:32304994 DOI: https://doi.org/10.1016/j.intimp.2020.106504
Zhou Y, Yang Q, Ye J, Wu X, Feng Y, Luo B, et al. Clinical features and death risk factors in COVID-19 patients with cancer: A retrospective study. BMC Infect Dis. 2021;21(1):760. https://doi.org/10.1186/s12879-021-06495-9 PMid:34353293 DOI: https://doi.org/10.1186/s12879-021-06495-9
Zhang B, Yu Y, Hubert SM, Zhang Y, Lu J, Liu S, et al. Prognostic value of pro-inflammatory neutrophils and C-reactive protein in cancer patient with coronavirus disease 2019: A multi-center, Retrospective Study. Front Pharmacol. 2020;11:576994. https://doi.org/10.3389/fphar.2020.576994 PMid:33192519 DOI: https://doi.org/10.3389/fphar.2020.576994
Downloads
Published
How to Cite
License
Copyright (c) 2022 Kamal Basri Siregar, Arjumardi Azrah, Citra Aryanti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
